BIO Asia–Taiwan 2022 亞洲生技大會

BIO Asia–Taiwan 2022 亞洲生技大會

講師

Dominik Witzigmann

Session 5 – New Modalities to Cure

Date:27 July (Wednesday)
Time:  15:40 – 17:10 (GMT+8)

Dominik Witzigmann

Chief Executive Officer
NanoVation Therapeutics

Dominik obtained his Ph.D. in Pharmaceutical Technology from the University of Basel in Switzerland. Following research projects at the University College London (toxicity), German Cancer Research Center (RNAi and cancer), University of Basel (targeted nanomedicines and DNA delivery) and the University of Zurich (mRNA-based genome editing), Dominik joined the team of Prof. Pieter Cullis at the University of British Columbia to focus on RNA delivery utilizing lipid nanoparticle (LNP) systems. Dominik had leadership roles within the NanoMedicines Innovation Network (NMIN - a Canadian Networks of Centres of Excellence), he co-founded and led NMIN`s NanoCore to support >30 projects with advanced nucleic acid delivery technologies, and he served as a Board Member of the Controlled Release Society Focus Group “Gene Delivery and Genome Editing”. Dominik has a proven track record in nanomedicines enabling tissue as well as cell specific drug and gene delivery. To translate next-generation LNP technologies into the clinic, Dr. Witzigmann co-founded and leads the LNP-nucleic acid company NanoVation Therapeutics.
 

Speech title & Synopsis

Tailoring lipid nanoparticles to enable RNA delivery to a variety of tissues.

We are at the most exciting point in human history with respect to the launch and development of nucleic acid therapeutics. The major challenge we currently face is access to state-of-the-art delivery technologies to target diseased tissue safely and effectively. To enable the delivery of nucleic acids to a variety of (extra)hepatic tissues, NanoVation has developed a one-stop-shop lipid nanoparticle (LNP) toolbox. NanoVation`s technology portfolio encompasses methods of synthesizing lipids, specialty (ionizable) lipids, LNP compositions, surface-modifying lipids such as PEG-alternatives, as well as mRNA modifications. Our flagship technology, the long-circulating LNP (lcLNP™) platform, enables functional nucleic acid delivery to extrahepatic tissues such as bone marrow, tumors, or skin following intravenous injection. NanoVation`s expertise, platform technologies and services enable partners to rapidly develop their life-changing gene therapies.